ACON and ACONW Related Headlines
Go Back- Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
- Aclarion partners with PRIA Healthcare for Nociscan reimbursement strategy
- Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
- Aclarion rejects Echo Lake Capital's $4 per share acquisition offer
- Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
- Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
- Aclarion partners with Institute of Neuro Innovation for Nociscan expansion
- Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion technology used in back pain study exploring immune factors
- Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
- Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
- Aclarion adds Beverly Hills spine practice to CLARITY trial
- Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
- Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
- Aclarion signs second commercial deal with Weill Cornell Medicine
- Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
- Aclarion reports 196% growth in scan volumes for Q1
- Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
- Aclarion names Daniel Keefe commercial director for western US
- Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
- Aclarion authorizes $2.5 million share repurchase program
- Aclarion Announces $2.5 Million Stock Repurchase Plan
- Aclarion receives US patent for AI-driven chronic low back pain platform
- Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
- Aclarion Receives Pinnacle Award for AI Innovation
- Aclarion partners with Weill Cornell Medicine for spine pain study
- Aclarion Announces Agreement with Weill Cornell Medicine
- Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
- Aclarion adopts one-year stockholder rights plan
- Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
- Aclarion publishes CEO letter on reimbursement progress and trial timeline
- Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
- Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
- Aclarion CEO Brent Ness to Attend LSI USA 2026
- Aclarion says cash runway extends into 2028, ends equity facilities
- Aclarion Publishes 2026 Shareholder Letter from the Chairman
- Aclarion partners with Source Healthcare to expand Nociscan in Los Angeles
- Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion raises $10.4 million, extends cash runway into 2028
- Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
- Aclarion reports 114% quarterly growth in scan volumes, raises $22M
- Aclarion Provides 2025 Update and 2026 Corporate Outlook
- Aclarion enrolls first patients at Northwestern, Scripps sites for CLARITY trial
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
- Aclarion publishes Nociscan article in spine surgery journal
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
- Aclarion names Jason Brosniak commercial director for eastern U.S.
- Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
- Aclarion hires Dan Isherwood as UK commercial director
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
- Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion reports 89% surge in scan volumes, advances trial
- Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
- Aclarion presents MR spectroscopy pain biomarker tech at London conference
- Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
- Aclarion to Present at the LD Micro Main Event XIX
- Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
- First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
- Aclarion names Greg Gould as chief financial officer
- Aclarion Appoints Greg Gould as Chief Financial Officer
- Aclarion reports 132% growth in Nociscan scan volume
- Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
- Aclarion (ACON) postpones annual shareholder meeting to July 21
- Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
- First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
- Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
ACON and ACONW Related Press Releases
Go Back- Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
- Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
- Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
- Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
- Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
- Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
- Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
- Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
- Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
- Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
- Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
- Aclarion Announces $2.5 Million Stock Repurchase Plan
- Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
- Aclarion Receives Pinnacle Award for AI Innovation
- Aclarion Announces Agreement with Weill Cornell Medicine
- Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
- Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
- Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
- Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
- Aclarion CEO Brent Ness to Attend LSI USA 2026
- Aclarion Publishes 2026 Shareholder Letter from the Chairman
- Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
- Aclarion Provides 2025 Update and 2026 Corporate Outlook
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
- Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
- Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
- Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
- Aclarion to Present at the LD Micro Main Event XIX
- Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
- First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
- Aclarion Appoints Greg Gould as Chief Financial Officer
- Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
- Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
- First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
- Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
